Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): A randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure

American Heart Journal

Volumn 166, Issue 4, 2013, Pages

  Fox, Kim ^a   Ford, Ian ^b   Steg, Philippe Gabriel ^c,d,e   Tardif, Jean Claude ^f   Tendera, Michal ^g   Ferrari, Roberto ^h  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c BICHAT HOSPITAL   (France)

^d INSERM   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f MONTREAL HEART INSTITUTE   (Canada)

^g MEDICAL UNIVERSITY OF SILESIA   (Poland)

^h UNIVERSITY HOSPITAL OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IVABRADINE; PLACEBO;

ADULT; AGED; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ELECTROCARDIOGRAM; FEMALE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OUTCOME ASSESSMENT; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTING HEART RATE; SINUS RHYTHM;

EID: 84885173675     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2013.06.024     Document Type: Article

References (28)

1. V.L. Roger, A.S. Go, and D.M. Lloyd-Jones Heart disease and stroke statistics - 2011 update: a report from the American Heart Association Circulation 123 2011 e18 e209
2. E.S. Ford, and S. Capewell Coronary heart disease mortality among young adults in the U.S. from 1980 through 2002: concealed leveling of mortality rates J Am Coll Cardiol 50 2007 2128 2132
3. K. Fox, J.S. Borer, and A.J. Camm Resting heart rate in cardiovascular disease J Am Coll Cardiol 50 2007 823 830
4. K.M. Fox, and R. Ferrari Heart rate: a forgotten link in coronary artery disease? Nat Rev Cardiol 8 2011 369 379
5. A. Diaz, M.G. Bourassa, and M.C. Guertin Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease Eur Heart J 26 2005 967 974
6. W.B. Kannel, C. Kannel, and R.S.J.R. Paffenbarger Heart rate and cardiovascular mortality: the Framingham Study Am Heart J 113 1987 1489 1494
7. M. Böhm, K. Swedberg, and M. Komajda Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial Lancet 376 2010 886 894
8. S.D. Fihn, J.M. Gardin, and J. Abrams 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/ STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons Circulation 126 2012 e354 e471
9. U.E. Heidland, and B.E. Strauer Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption Circulation 104 2001 1477 1482
10. P.H. Stone, S. Saito, and S. Takahashi Prediction of progression of coronary artery disease and clinical outcomes using vascular profiling of endothelial shear stress and arterial plaque characteristics: the PREDICTION Study Circulation 126 2012 172 181
11. K. Fox, I. Ford, and P.G. Steg Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial Lancet 372 2008 817 821
12. R. Kolloch, U.F. Legler, and A. Champion Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST) Eur Heart J 29 2008 1327 1334
13. R.J. Gibbons, J. Abrams, and K. Chatterjee ACC/AHA 2002 guideline update for the management of patients with chronic stable angina - summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina) J Am Coll Cardiol 41 2003 159 168
14. f current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease Drugs 64 2004 1757 1765
15. J.P. Vilaine, J.P. Bidouard, and L. Lesage Anti-ischemic effects of ivabradine, a selective heart rate-reducing agent, in exercise-induced myocardial ischemia in pigs J Cardiovasc Pharmacol 42 2003 688 696
16. P. Mulder, S. Barbier, and A. Chagraoui Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure Circulation 109 2004 1674 1679
17. L. Simon, B. Ghaleh, and L. Puybasset Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs J Pharmacol Exp Ther 275 1995 659 666
18. J.C. Tardif, P. Ponikowski, and T. Kahan Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4 month, randomized, placebo-controlled trial Eur Heart J 30 2009 540 548
19. J.C. Tardif, I. Ford, and M. Tendera Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina Eur Heart J 26 2005 2529 2536
20. K. Swedberg, M. Komajda, and M. Böhm Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled trial Lancet 376 2010 875 885
21. K. Fox, M. Komajda, and I. Ford Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials Eur Heart J 34 2013 2263 2270
22. K. Fox, I. Ford, and P.G. Steg Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial Lancet 372 2008 807 816
23. K. Fox, I. Ford, and P.G. Steg Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial Eur Heart J 30 2009 2337 2345
24. K. Kotseva, D. Wood, and B.G. De Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries Lancet 373 2009 929 940
25. W.B. Borden, R.F. Redberg, and A.I. Mushlin Patterns and intensity of medical therapy in patients undergoing percutaneous coronary intervention JAMA 305 2011 1882 1889
26. D.L. Bhatt, P.G. Steg, and E.M. Ohman International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis JAMA 295 2006 180 189
27. P.G. Steg, R. Ferrari, and I. Ford Heart rate and use of beta-blockers in stable outpatients with coronary artery disease PLoS One 7 2012 e36284
28. C.A. Daly, F. Clemens, and J.L. Sendon The clinical characteristics and investigations planned in patients with stable angina presenting to cardiologists in Europe: from the Euro Heart Survey of Stable Angina Eur Heart J 26 2005 996 1010